Assessment of harms, benefits, and cost-effectiveness of prostate cancer screening: A micro-simulation study of 230 scenarios.

ABSTRACT:

Background

Prostate cancer screening incurs a high risk of overdiagnosis and overtreatment. An organized and age-targeted screening strategy may reduce the associated harms while retaining or enhancing the benefits.

Methods

Using a micro-simulation analysis (MISCAN) model, we assessed the harms, benefits, and cost-effectiveness of 230 prostate-specific antigen (PSA) screening strategies in a Dutch population. Screening strategies were varied by screening start age (50, 51, 52, 53, 54, and 55), stop age (51-69), and intervals (1, 2, 3, 4, 8, and single test). Costs and effects of each screening strategy were compared with a no-screening scenario.

Results

The most optimum strategy would be screening with 3-year intervals at ages 55-64 resulting in an incremental cost-ef

SUBMITTER: Getaneh AM 

PROVIDER: S-EPMC7571827 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature